Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 27

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 27
---
 savings or synergies.
We also may not achieve the anticipated benefits from the acquired business due to a number of factors, including:

    ●
    incurrence
    of acquisition-related costs;

    ●
    diversion
    of management’s attention from other business concerns;

    ●
    unanticipated
    costs or liabilities associated with the acquisition;

    ●
    harm
    to our existing business relationships with collaboration partners as a result of the acquisition;

    ●
    harm
    to our brand and reputation;

    ●
    the
    potential loss of key employees;

    ●
    use
    of resources that are needed in other parts of our business; and

    ●
    use
    of substantial portions of our available cash to consummate the acquisition.

36

In
the future, if our acquisitions do not yield expected returns, we may be required to take charges to our operating results arising from
the impairment assessment process. Acquisitions may also result in dilutive issuances of equity securities or the incurrence of debt,
which could adversely affect our operating results. In addition, if an acquired business fails to meet our expectations, our business,
results of operations and financial condition may be adversely affected.

Risks
Related to Development and Regulatory Approval of Our Product Candidates

Clinical
trials for our product candidates are expensive, time-consuming, uncertain, and susceptible to change, delay or termination. The results
of clinical trials are open to differing interpretations.

Clinical
trials are expensive, time consuming and difficult to design and implement. Regulatory agencies may analyze or interpret the results
differently than us. Even if the results of our clinical trials are favorable, the clinical trials for a number of our product candidates
are expected to continue for several years and may take significantly longer to complete. In addition, we, the FDA, or other regulatory
authorities, including state and local authorities, or an Institutional Review Board, or IRB, with respect to a trial at its institution,
may suspend, delay or terminate our clinical trials at any time, require us to conduct additional clinical trials, require a particular
clinical trial to continue for a longer duration than originally planned, require a change to our development plans such that we conduct
clinical trials for a product candidate in a different order, e.g., in a step-wise fashion rather than running two trials of the same
product candidate in parallel, or the DEA could suspend or terminate the registrations and quota allotments we require in order to procure
and